U.s. investigator-initiated trial (iit) to evaluate jaguar health's crofelemer for short bowel syndrome with intestinal failure (sbs-if) begins

The study is one of five clinical efforts - three iit proof-of-concept studies and two phase 2 studies - of crofelemer for the rare disease indications of sbs-if and/or microvillus inclusion disease (mvid), an ultrarare congenital diarrheal disorder, in the us, eu, and/or middle east/north africa (mena) regions; availability of iit proof-of-concept results potentially in q2 2025 crofelemer, jaguar's novel plant-based prescription drug, has been granted orphan drug designation by the fda and the european medicines agency for both sbs-if and mvid san francisco, ca / accesswire / december 6, 2024 / jaguar health, inc. (nasdaq:jagx) (jaguar) family company napo pharmaceuticals (napo) today announced that an independent iit in the u.s. to evaluate the efficacy and safety of crofelemer, jaguar's novel plant-based anti-diarrheal prescription drug, for the rare disease indication of short bowel syndrome with intestinal failure (sbs-if) in adults has begun. an overview of the study can be viewed on the clinicaltrials.gov website.
JAGX Ratings Summary
JAGX Quant Ranking